Insider Selling: Dexcom (DXCM) Insider Sells 10,000 Shares of Stock

Dexcom (NASDAQ:DXCM) insider Terrance H. Gregg sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 16th. The stock was sold at an average price of $73.04, for a total transaction of $730,400.00. Following the completion of the sale, the insider now owns 521,674 shares in the company, valued at $38,103,068.96. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Dexcom stock traded up $0.08 during trading hours on Wednesday, hitting $73.50. The company had a trading volume of 771,425 shares, compared to its average volume of 1,274,148. The firm has a market cap of $6,356.88, a PE ratio of -126.72 and a beta of -0.01. The company has a debt-to-equity ratio of 0.78, a quick ratio of 5.04 and a current ratio of 5.36. Dexcom has a fifty-two week low of $42.62 and a fifty-two week high of $81.91.

How to Become a New Pot Stock Millionaire

Dexcom (NASDAQ:DXCM) last released its quarterly earnings data on Tuesday, February 27th. The medical device company reported $0.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.03 by $0.07. The firm had revenue of $221.00 million for the quarter, compared to analyst estimates of $217.82 million. Dexcom had a negative net margin of 6.99% and a negative return on equity of 13.99%. equities analysts anticipate that Dexcom will post -0.56 EPS for the current fiscal year.

A number of analysts recently commented on DXCM shares. BidaskClub downgraded shares of Dexcom from a “buy” rating to a “hold” rating in a report on Tuesday, February 27th. Zacks Investment Research upgraded shares of Dexcom from a “sell” rating to a “hold” rating in a report on Friday, March 16th. Northcoast Research restated a “buy” rating on shares of Dexcom in a report on Sunday, March 4th. Piper Jaffray set a $78.00 price target on shares of Dexcom and gave the company a “buy” rating in a report on Friday, March 23rd. Finally, ValuEngine lowered shares of Dexcom from a “hold” rating to a “sell” rating in a report on Thursday, February 8th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $67.38.

A number of institutional investors have recently added to or reduced their stakes in the business. Amalgamated Bank increased its stake in Dexcom by 5.7% in the 4th quarter. Amalgamated Bank now owns 17,107 shares of the medical device company’s stock valued at $982,000 after buying an additional 924 shares during the period. Wedbush Securities Inc. increased its stake in Dexcom by 24.2% in the 4th quarter. Wedbush Securities Inc. now owns 5,589 shares of the medical device company’s stock valued at $321,000 after buying an additional 1,089 shares during the period. Dimensional Fund Advisors LP increased its stake in Dexcom by 0.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 127,769 shares of the medical device company’s stock valued at $6,247,000 after buying an additional 1,095 shares during the period. Stifel Financial Corp increased its stake in Dexcom by 15.2% in the 3rd quarter. Stifel Financial Corp now owns 8,567 shares of the medical device company’s stock valued at $422,000 after buying an additional 1,129 shares during the period. Finally, Teachers Advisors LLC increased its stake in Dexcom by 1.7% in the 4th quarter. Teachers Advisors LLC now owns 92,801 shares of the medical device company’s stock valued at $5,326,000 after buying an additional 1,584 shares during the period.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Dexcom (DXCM) Insider Sells 10,000 Shares of Stock” was published by Week Herald and is the property of of Week Herald. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://weekherald.com/2018/04/18/insider-selling-dexcom-dxcm-insider-sells-10000-shares-of-stock.html.

About Dexcom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Insider Buying and Selling by Quarter for Dexcom (NASDAQ:DXCM)

Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply